CAPR · As filed with the SEC
Capricor Therapeutics cash flow statement, by quarter
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q4 2024 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||
| Net loss | — | (33,941,345) | — | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
| Depreciation and amortization | — | 534,670 | — | — | — | — |
| Stock-based compensation | — | 5,918,055 | — | — | — | — |
| Amortization/accretion of note premiums/discounts | — | (358,625) | — | — | — | — |
| Changes in lease liabilities | — | 641,285 | — | — | — | — |
| Other | — | (6,591) | — | — | — | — |
| Changes in operating assets and liabilities: | ||||||
| Receivables | — | 59,167 | — | — | — | — |
| Prepaid expenses and other assets | — | 979,776 | — | — | — | — |
| Accounts payable and accrued expenses | — | (3,081,283) | — | — | — | — |
| Net cash used in operating activities | — | (29,254,891) | — | — | — | — |
| Cash flows from investing activities: | ||||||
| Purchase of marketable securities | — | (174,893,062) | — | — | — | — |
| Proceeds from sales and maturities of marketable securities | — | 30,998,448 | — | — | — | — |
| Purchases of property and equipment | — | (5,121,709) | — | — | — | — |
| Payments for leasehold improvements | — | (921,752) | — | — | — | — |
| Payments for construction in progress | — | (4,703,521) | — | — | — | — |
| Net cash provided by (used in) investing activities | — | (154,641,596) | — | — | — | — |
| Cash flows from financing activities: | ||||||
| Proceeds from exercise of stock options | — | 1,470,659 | — | — | — | — |
| Net cash provided by (used in) financing activities | — | 1,470,659 | — | — | — | — |
| Net increase (decrease) in cash and cash equivalents | — | (182,425,828) | — | — | — | — |
| Cash and cash equivalents balance at beginning of period | 105,421,484 | 287,847,312 | 19,510,383 | 23,241,199 | 28,794,503 | 68,377,402 |
| Cash and cash equivalents balance at end of period | 20,935,187 | 105,421,484 | 287,847,312 | 19,510,383 | 23,241,199 | 11,286,996 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.